{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=mirabegron&page=2",
    "query": {
      "intervention": "mirabegron",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=mirabegron&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-19T14:34:49.431Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04766021",
      "title": "Mirabegron and Physiological Function in Cold Environments",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Resting Energy Expenditure",
        "Thermogenesis",
        "Brown Adipose Tissue"
      ],
      "interventions": [
        {
          "name": "Mirabegron",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Indiana University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "18 Years to 40 Years"
      },
      "enrollment_count": 30,
      "start_date": "2021-11-30",
      "completion_date": "2023-04-27",
      "has_results": true,
      "last_update_posted_date": "2024-07-12",
      "last_synced_at": "2026-09-19T14:34:49.431Z",
      "location_count": 1,
      "location_summary": "Bloomington, Indiana",
      "locations": [
        {
          "city": "Bloomington",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04766021"
    },
    {
      "nct_id": "NCT02386072",
      "title": "A Prospective, Observational, Multicenter Study of Patients Following Initiation of a New Course of Treatment for Overactive Bladder (OAB)",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Urinary Bladder Overactive",
        "Overactive Bladder",
        "Urinary Bladder Diseases",
        "Urologic Diseases"
      ],
      "interventions": [
        {
          "name": "mirabegron",
          "type": "DRUG"
        },
        {
          "name": "antimuscarinic medication",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Scientific & Medical Affairs, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1524,
      "start_date": "2015-01-05",
      "completion_date": "2017-08-04",
      "has_results": false,
      "last_update_posted_date": "2024-10-16",
      "last_synced_at": "2026-09-19T14:34:49.431Z",
      "location_count": 75,
      "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 56 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Goodyear",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02386072"
    },
    {
      "nct_id": "NCT03817931",
      "title": "Higher Neural Changes Following Anticholinergic, Beta 3 Agonist, or Placebo in Patients With Overactive Bladder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Overactive Bladder",
        "Dementia",
        "Lower Urinary Tract Symptoms",
        "Incontinence, Urge"
      ],
      "interventions": [
        {
          "name": "Anticholinergic",
          "type": "DRUG"
        },
        {
          "name": "Beta-3 Agonists, Adrenergic",
          "type": "DRUG"
        },
        {
          "name": "Functional magnetic resonance imaging (fMRI)",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Rey Auditory Verbal Learning Test (RAVLT)",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Baylor Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 90 Years · Female only"
      },
      "enrollment_count": 12,
      "start_date": "2019-08-05",
      "completion_date": "2022-02-26",
      "has_results": false,
      "last_update_posted_date": "2024-02-02",
      "last_synced_at": "2026-09-19T14:34:49.431Z",
      "location_count": 2,
      "location_summary": "Houston, Texas • Temple, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Temple",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03817931"
    },
    {
      "nct_id": "NCT05880862",
      "title": "Comparative Effectiveness of Initial OAB Treatment Options Among Older Women at High Risk of Falls",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Urinary Bladder, Overactive",
        "Urinary Incontinence",
        "Accidental Falls"
      ],
      "interventions": [
        {
          "name": "Pelvic Floor Muscle Training",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Mirabegron",
          "type": "DRUG"
        },
        {
          "name": "Trospium Chloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "DRUG"
      ],
      "sponsor": "The University of Texas Medical Branch, Galveston",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": "99 Years",
        "sex": "FEMALE",
        "summary": "60 Years to 99 Years · Female only"
      },
      "enrollment_count": 48,
      "start_date": "2023-09-28",
      "completion_date": "2025-12-27",
      "has_results": false,
      "last_update_posted_date": "2026-06-22",
      "last_synced_at": "2026-09-19T14:34:49.431Z",
      "location_count": 1,
      "location_summary": "Galveston, Texas",
      "locations": [
        {
          "city": "Galveston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05880862"
    },
    {
      "nct_id": "NCT02757768",
      "title": "A Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Men With OAB Symptoms While Taking Tamsulosin Hydrochloride for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Benign Prostatic Hyperplasia",
        "Overactive Bladder"
      ],
      "interventions": [
        {
          "name": "Mirabegron",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Tamsulosin Hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Global Development, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "40 Years and older · Male only"
      },
      "enrollment_count": 715,
      "start_date": "2016-06-13",
      "completion_date": "2018-09-11",
      "has_results": true,
      "last_update_posted_date": "2024-11-12",
      "last_synced_at": "2026-09-19T14:34:49.431Z",
      "location_count": 32,
      "location_summary": "Homewood, Alabama • Huntsville, Alabama • Anchorage, Alaska + 27 more",
      "locations": [
        {
          "city": "Homewood",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Hawaiian Gardens",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02757768"
    },
    {
      "nct_id": "NCT03049462",
      "title": "The Physiological Responses and Adaptation of Brown Adipose Tissue to Chronic Treatment With Beta3-Adrenergic Receptor Agonists",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Polycystic Ovary Syndrome"
      ],
      "interventions": [
        {
          "name": "Mirabegron",
          "type": "DRUG"
        },
        {
          "name": "B Complex Plus Vitamin C Tablets",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "18 Years to 40 Years"
      },
      "enrollment_count": 55,
      "start_date": "2017-03-13",
      "completion_date": "2026-08-26",
      "has_results": false,
      "last_update_posted_date": "2026-09-09",
      "last_synced_at": "2026-09-19T14:34:49.431Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03049462"
    },
    {
      "nct_id": "NCT02092181",
      "title": "A Pilot Study of Mirabegron and Behavioral Modification Including Pelvic Floor Exercise for Overactive Bladder in Parkinson's Disease (MAESTRO)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Parkinsons Disease"
      ],
      "interventions": [
        {
          "name": "Mirabegron",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Daniel Burdick, MD",
      "sponsor_class": "INDIV",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "30 Years to 85 Years"
      },
      "enrollment_count": 30,
      "start_date": "2014-03",
      "completion_date": "2018-07-01",
      "has_results": true,
      "last_update_posted_date": "2021-08-16",
      "last_synced_at": "2026-09-19T14:34:49.431Z",
      "location_count": 1,
      "location_summary": "Kirkland, Washington",
      "locations": [
        {
          "city": "Kirkland",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02092181"
    },
    {
      "nct_id": "NCT02045862",
      "title": "A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Urinary Bladder Overactive",
        "Overactive Bladder",
        "Urgency Incontinence",
        "Urinary Bladder Diseases\\Urologic Diseases"
      ],
      "interventions": [
        {
          "name": "Solifenacin succinate",
          "type": "DRUG"
        },
        {
          "name": "Mirabegron",
          "type": "DRUG"
        },
        {
          "name": "Placebo to match solifenacin",
          "type": "DRUG"
        },
        {
          "name": "Placebo to match mirabegron",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Europe B.V.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1829,
      "start_date": "2014-03-17",
      "completion_date": "2016-09-08",
      "has_results": true,
      "last_update_posted_date": "2024-10-31",
      "last_synced_at": "2026-09-19T14:34:49.431Z",
      "location_count": 75,
      "location_summary": "Mobile, Alabama • Chandler, Arizona • Phoenix, Arizona + 61 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02045862"
    },
    {
      "nct_id": "NCT07829029",
      "title": "Ancillary Nocturnal Urinary Symptoms Analyses for TRIUMPH",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Nocturia",
        "Nocturnal Urinary Incontinence"
      ],
      "interventions": [
        {
          "name": "TolterodineTartrate ER",
          "type": "DRUG"
        },
        {
          "name": "Mirabegron",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "60 Years and older · Female only"
      },
      "enrollment_count": 270,
      "start_date": "2022-10-04",
      "completion_date": "2027-05-02",
      "has_results": false,
      "last_update_posted_date": "2026-09-18",
      "last_synced_at": "2026-09-19T14:34:49.431Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07829029"
    },
    {
      "nct_id": "NCT01199523",
      "title": "A Study to Evaluate the Effect of Oral Mirabegron on the Heart in Healthy Males and Females",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Subjects"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "mirabegron",
          "type": "DRUG"
        },
        {
          "name": "moxifloxacin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 352,
      "start_date": "2010-05",
      "completion_date": "2010-11",
      "has_results": false,
      "last_update_posted_date": "2013-07-03",
      "last_synced_at": "2026-09-19T14:34:49.431Z",
      "location_count": 2,
      "location_summary": "Glendale, California • Baltimore, Maryland",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01199523"
    }
  ]
}